Pulse Newsletter
Browse page 2 of our Pulse Newsletter articles in the Thrivous Views blog at Thrivous. They're listed below. If you prefer, you can also browse all articles in Thrivous Views. Or search for articles and other content on the Thrivous website.
-
Exploring the Link Between Spirituality and Longevity
Human enhancement, the application of science and technology to physically or mentally improve the human body beyond its current limitations, ...
-
Approaching Breakthroughs for Alzheimer's
We are living at a time when technology brings new hope to confront diseases like Alzheimer's as well as the ...
-
Anti-Aging Compounds and Brain-Computer Interfaces
Recent advances in technology and research are presenting innovative opportunities for human enhancement. These strides are pushing us closer towards ...
-
Delayed Aging and Exoskeletons for Human Enhancement
Welcome to the latest roundup of human enhancement news. We're sharing exciting breakthroughs in artificial intelligence, robotics, and longevity research ...
-
Long-Term Resistance Training Promotes Healthy Aging
Autophagy is an important process in cells that helps get rid of damaged or unnecessary parts. When it doesn't work ...
-
Epigenetic Engineering Rejuvenates Lab Mice
Scientists led by Harvard Medical School have shown that degradation in the way DNA is organized and regulated - known ...
-
Algae-Based Microrobots Deliver Life-Saving Drugs
Nanotechnology engineers at UC San Diego have developed microscopic robots, called "microrobots." They can swim around in the lungs, deliver ...
-
Chromosome Fusion Enables Accelerated Evolution
Chinese scientists have developed a new technique for programmable chromosome fusion. And they've used the new technique in the laboratory ...
-
Bioengineered Immune Cells for Deadly Genetic Disease
Immusoft, a biotechnology company based in Seattle, has announced that the US Food and Drug Administration (FDA) “has agreed to ...
-
Genetically-Modified Cancer-Killing Oncolytic Viruses
In May, City of Hope and Imugene Limited announced that the first patient was dosed in a phase 1 clinical ...
